Kalden J R, Manger B
Department of Internal Medicine III, University of Erlangen-Nuremberg, Germany.
Curr Opin Rheumatol. 1995 May;7(3):191-7. doi: 10.1097/00002281-199505000-00006.
Due to our increasing knowledge of mechanisms underlying pathogenic events in autoimmune rheumatic diseases, biologic agents have been further explored and tested in open and controlled clinical trials. Based on the results of placebo-controlled trials, monoclonal antibodies to CD4+ T cells have been found ineffective in treating rheumatoid arthritis. However, this type of monoclonal antibody might be useful for combination therapy with monoclonal antibody, against tumor necrosis factor-alpha. The most promising data have been collected from a placebo-controlled four-center study of monoclonal anti-tumor necrosis factor-alpha antibodies in rheumatoid arthritis patients. This type of treatment was demonstrated for the first time to effectively interfere with ongoing inflammatory processes. Undoubtedly, the progress in the development of biologic agents for the therapy of inflammatory rheumatic diseases is steadily improving. Thus, for the future, even better treatment principles for this group of diseases can be expected.
由于我们对自身免疫性风湿性疾病致病事件潜在机制的认识不断增加，生物制剂已在开放和对照临床试验中得到进一步探索和测试。基于安慰剂对照试验的结果，已发现针对CD4 + T细胞的单克隆抗体在治疗类风湿性关节炎方面无效。然而，这种类型的单克隆抗体可能对与抗肿瘤坏死因子-α单克隆抗体联合治疗有用。最有前景的数据来自一项针对类风湿性关节炎患者的抗肿瘤坏死因子-α单克隆抗体的安慰剂对照四中心研究。这种治疗方法首次被证明能有效干扰正在进行的炎症过程。毫无疑问，用于治疗炎性风湿性疾病的生物制剂的开发进展正在稳步改善。因此，未来有望为这组疾病制定出更好的治疗原则。
